Pemvidutide dosing & administration
Balanced dual GLP-1/glucagon receptor agonist with no dose titration required and breakthrough therapy designation for MASH.
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Dosing
How much do I take?
Subcutaneous: A small injection into the fatty layer just under the skin — the same way insulin is given.
Bioavailability High — most of the dose reaches your bloodstream, just more gradually than an IV.
Titration schedule
1.2 mg
Frequency
Once weekly
Duration
48 weeks
1.8 mg
Frequency
Once weekly
Duration
48 weeks
2.4 mg
Frequency
Once weekly
Duration
48 weeks
Highest dose; reached via a 4-week titration in MOMENTUM, where it produced 15.6% weight loss at 48 weeks [6].
Timing
Best time to take
Administer Pemvidutide at the same time each day (or on the same day each week for weekly injections). Many users prefer morning or evening administration. Pick a time you'll remember consistently.
With food?
Pemvidutide injections can be given regardless of meal timing. However, if GI effects occur, administering on an empty stomach or with a light meal may help reduce discomfort.
If stacking
Pemvidutide should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.
Adjusting your dose
Increase if
- You've tolerated the current dose for the recommended period without significant side effects
- Therapeutic goals haven't been met at the current dose level
- Your healthcare provider recommends dose escalation based on your response
- Lab work or clinical assessments support a higher dose
Decrease if
- Side effects are bothersome or impacting daily life despite management strategies
- You experience any signs of an adverse reaction
- Lab results indicate the need for dose reduction
- Your healthcare provider recommends a lower dose based on your response
Signs of right dose
- Therapeutic goals being met with minimal side effects
- Stable and consistent response to treatment
- Lab values or clinical markers trending in the right direction
- Good tolerance with manageable or absent side effects
Administration
How do I use it?
Reconstitution
What you need
Injection
Route
Subcutaneous injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training
Best sites
Storage
Before reconstitution
Store Pemvidutide in the refrigerator at 36-46°F (2-8°C) in its original packaging. Protect from light and moisture. Do not freeze. Check the expiration date before use. Some formulations may be stored at room temperature for limited periods—check your specific product labeling.
After reconstitution
Once reconstituted, Pemvidutide should be kept refrigerated at 36-46°F (2-8°C) and used within the timeframe specified on your product labeling (typically 14-28 days). Label the vial with the reconstitution date. Do not use if the solution appears cloudy, discolored, or contains particles.
Signs of degradation — discard the vial
Sample daily schedule
As prescribed (once daily)
As prescribed by your healthcare provider injection
Site: Subcutaneous injection—rotate sites if applicable
Maintain a consistent schedule for optimal results with Pemvidutide. Set reminders if needed. If you miss a dose, follow your healthcare provider's instructions—do not double up on doses to compensate.
Safety
Is it safe?
Side effects
Commonly reported: Nausea, Diarrhea, Headache
Less common: Vomiting, Decreased Appetite
Stop and seek help if
- Severe or worsening side effects that don't improve with dose adjustment or supportive care
- Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
- Your healthcare provider recommends discontinuation based on your clinical response
- Development of any new medical condition that may be contraindicated with Pemvidutide
- Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
- Abnormal lab results or clinical markers that suggest adverse effects
Pemvidutide should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
Flagged pairings
- Other GLP-1 Receptor Agonists — Use with caution—discuss with your healthcare provider.
- Sulfonylureas — Use with caution—discuss with your healthcare provider.
- Insulin (without dose adjustment) — Use with caution—discuss with your healthcare provider.
Published research
What the studies show
Noureddin M, et al. · 2025
Pemvidutide, a dual GLP-1/glucagon agonist, achieved MASH resolution without fibrosis worsening in 58% of patients at 1.2 mg dose versus 20% placebo after 24 weeks. Both doses demonstrated safety with primarily mild gastrointestinal side effects.
Browne SK, et al. · 2025
No abstract available for comprehensive analysis.
Harrison SA, et al. · 2025
Weekly pemvidutide treatment reduced liver fat content by 46.6-68.5% depending on dose, with 72.2% achieving 50% fat reduction. Weight loss and inflammatory markers improved significantly without serious adverse events.
Kaya E, et al. · 2025
This review highlighted emerging hepatoprotective drugs for MASH, with GLP-1 and dual agonists like pemvidutide playing significant roles in managing metabolic dysfunction-associated steatohepatitis.
Nestor JJ, et al. · 2022
ALT-801, a GLP-1/glucagon dual agonist, achieved 25% body weight reduction in obese mice with NASH, greater than semaglutide alone. The dual agonism showed superior liver fibrosis and inflammation reduction.
Aronne L, Harris MS, Roberts MS, Suschak JJ, Tomah S, Kasper J, He L, Yang J, Frias JP, Browne SK · 2024
Altimmune, Inc. · 2025
Head to head
Pemvidutide compared
Want the full picture?
The complete Pemvidutide research profile: mechanism of action, clinical studies, effectiveness timeline, and FAQ.